TrialThe Journal of dermatology2019

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.

Mamitaro Ohtsuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.